Antibodies- Vaccine Research & Biosimilars
| Principal | Key Products | About Key Products |
|---|---|---|
| Absolute Antibody
|
Anti Allergen Antibodies | Absolute Antibody offers a range of antibodies against common allergens. Many of these antibodies have been shown to compete with naturally occurring IgE – the principal antibody isotype mediating allergies. We offer these antibodies as human IgE (along with antibodies against IgE itself) for use as calibrators and positive controls. |
| Anti Virus Antibodies | Absolute Antibody offers a range of recombinant antibodies against viral antigens. | |
| Research Grade Biosimilar Antibodies Absolute Antibody | Absolute Antibody research-grade biosimilars are research tools for the study and evaluation of biological processes without the need to source and purchase costly therapeutic-grade biologics. Free of excipients and/or additives found in the therapeutic formulations, our biosimilars require fewer extra controls in an experimental setting. In addition to the original human format, our biosimilars are available with mouse, rabbit, rhesus monkey and cynomolgus monkey constant domains. | |
| rhAntibodies from Human Patients | Absolute Antibody offers a range of recombinant antibodies are high-quality recombinant versions of human-derived antibodies specific to viral pathogens or self-antigens. We offer the original human IgG version as well as reformatted mouse and rabbit versions to suit your experimental requirements. | |
Origene |
Research Grade Biosimilar Antibodies | Origene research-grade biosimilars Antibodies are research tools for analysis of biological processes without the need to purchase expensive therapeutic-grade biologics. |
| Targetmol
|
Inhibitory Antibodies (Biosimilars) | TargetMol provides 30 monoclonal antibody drugs, including the immune checkpoint (PD-1, PD-L1, and CTLA-4) inhibitors and other types of targeted antibody inhibitors, for scientific research only. |
| Leinco
|
Biosimilar (Human) Research Grade Antibodies | Leinco’s biosimilars are made available to researchers to avoid purchasing therapeutic antibodies at pharmaceutical prices for important groundbreaking experiments. |
